Oncology

For women with resistant ovarian cancer, options are few. A new drug, NTB-928, uses a dual-key design to unlock the immune system against tumors.

Behind the headlines of cancer breakthroughs lies a booming market for specialized research firms. Discover how CROs are becoming the new engine of oncology innovation.

Florida Cancer Specialists' latest hires in Ocala are more than a local news item; they're a calculated move in the battle for oncology market dominance.

Intensity Therapeutics shows promising results for its cancer-killing drug, but can it navigate the biotech funding crunch and land a vital pharma partner?

A new company is launching an AI-powered specialty to detect cancer before it forms. But can this personalized, oncologist-led model overcome hurdles of cost and access?

A new transatlantic partnership leverages AI and a £5.25M philanthropic gift to accelerate the discovery of kinder, more effective treatments for children.

A breakthrough melanoma test from SkylineDx has earned rare dual recognition, promising to reshape patient care by reducing unnecessary surgeries.

Candel Therapeutics is betting its future on a pivotal Phase 3 trial for a novel viral immunotherapy, aiming to succeed where checkpoint inhibitors have failed.

With an $85M insider-led round and a seasoned M&A expert as CEO, Flare Therapeutics sharpens its focus on a novel prostate cancer drug, FX-111.

Allarity Therapeutics just secured a patent until 2042 for its cancer diagnostic. Is this the key to unlocking personalized treatment or a risky biotech bet?

New data reveals how Genelux’s oncolytic virus reawakens chemotherapy's power, offering a potential lifeline in a notoriously difficult-to-treat cancer.

Plus Therapeutics rebrands to Cerenome, signaling a major pivot to an integrated platform combining diagnostics, radiotherapeutics, and AI for CNS cancers.

Interim data for Pasithea Therapeutics' PAS-004 shows durable activity and superior safety, offering a new strategy for patients who have run out of options.

Novocure's Optune Pax device, using Tumor Treating Fields, gains European approval, offering extended survival and significant pain relief for a deadly disease.

Positive Phase 3 data for BRUKINSA shows a 43% reduction in cancer progression, heralding a chemotherapy-free future for frontline mantle cell lymphoma.

A landmark public-private partnership brings next-gen proton therapy to Portugal, ending medical exile for patients and creating a new European oncology hub.

A new chemo-free combo from Genmab and AbbVie shows a 60% reduction in disease progression for a tough-to-treat blood cancer, setting a new standard.

A retired NYC prosecutor's daily commute to NJ for cancer treatment reveals a larger story about specialized tech, patient choice, and a shifting healthcare landscape.

A new 'radical collaboration' between top cancer centers is leveraging recent drug breakthroughs to develop combination therapies for pancreatic cancer's deadliest mutation.

A landmark FDA decision on Trodelvy reshapes metastatic TNBC care, offering new hope while directly confronting deep-seated racial disparities in treatment.